查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1927687

全球真实世界证据肿瘤市场：按组件、资料来源类型、治疗领域、应用、最终用户、国家和地区划分－产业分析、市场规模、份额和预测（2025-2032）

RWE Oncology Market, By Component, By Data Source Type, By Therapeutic Area, By Application, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 380 Pages | 商品交期: 2-3个工作天内

价格
简介目录

预计到 2024 年，RWE 肿瘤市场规模将达到 7.901 亿美元，并从 2025 年到 2032 年以 14.90% 的复合年增长率成长。

肿瘤学领域的真实世界证据 (RWE) 指的是收集和分析来自真实世界环境（例如电子健康记录、患者登记和保险理赔数据）的健康数据，以补充临床试验结果。这些证据支持治疗效果检验、安全性监测和个人化癌症治疗决策。市场成长的驱动力来自癌症发生率的上升和基于价值的医疗保健模式的广泛应用。根据美国国家癌症研究所 (NCI) 预测，2024 年美国将新增约 190 万例癌症病例，这进一步增加了对真实世界数据的需求，以改善治疗效果。随着数据分析技术的进步、人工智慧的整合以及监管机构的认可，RWE 的应用正在加速癌症药物的研发，并优化全球患者管理。

真实世界证据肿瘤市场动态

更多采用真实世界数据来改善癌症治疗效果

全球癌症负担日益加重，对个人化、实证肿瘤治疗的需求不断增长，推动了对真实世界证据（RWE）解决方案的需求。世界卫生组织（WHO）指出，癌症仍是全球首要死因，预计到2024年将有约1,000万人死于癌症。这种情况促使人们更加重视利用电子健康记录、癌症登记处和理赔资料库的真实世界数据，以补充临床试验，提高治疗效果和安全性监测。美国食品药物管理局（FDA）等监管机构正越来越多地采用RWE来支持药物核准和适应症扩展，加速市场应用。人工智慧和机器学习的进步使得人们能够从复杂的肿瘤数据中获得更深入的洞察，并推动精准医疗的发展。此外，支付者和医疗服务提供者正在强调以价值为基础的医疗模式，利用RWE来优化治疗通讯协定并降低成本。对医疗资讯IT基础设施的投资不断增加，尤其是在已开发经济体和新兴经济体，进一步推动了全球成长机会。

真实世界肿瘤市场：細項分析

全球 RWE 肿瘤市场按组件、资料来源类型、治疗领域、应用、最终用户和地区进行细分。

从组成元件来看，该平台由资料来源、分析软体和服务所构成。资料来源包括电子健康记录(EHR)、癌症登记资料、理赔和报销资料、病患报告结果以及基因组资料库，提供对肿瘤学研究至关重要的多样化真实世界资讯。分析软体利用人工智慧和机器学习演算法分析复杂的肿瘤学资料集，以评估治疗效果、安全性和预测预后。服务包括咨询、数据管理和集成，旨在帮助医疗保健相关人员高效实施真实世界证据 (RWE) 解决方案。根据美国国家卫生资讯科技协调办公室 (ONC) 预测，到 2024 年，医院中经认证的 EHR 技术采用率将超过 85%，从而为 RWE 提供资料支援。

应用领域涵盖药物研发和临床试验、治疗方案优化、监管和支付方决策支持，以及市场进入和医保报销。在药物研发方面，真实世界证据（RWE）可与临床试验相辅相成，加速核准并扩大适应症。在治疗方案优化方面，患者数据可用于个人化治疗，进而改善治疗效果。在监管和支付方决策支援方面，真实世界资料可用于安全性监测和医疗保险报销决策。在市场进入和健保报销方面，RWE 透过展现治疗方案的价值和成本效益而获益，在与支付方谈判和纳入健保目录方面发挥着至关重要的作用。

真实世界证据肿瘤市场—区域分析

全球真实世界证据（RWE）肿瘤市场呈现显着的区域差异，这主要受医疗基础设施、数据可用性和法规结构的影响。北美市场主导，美国国家癌症研究所（NCI）预测，2024年美国新增癌症病例将超过190万例，这将推动对真实世界数据的需求，以改善治疗效果。美国食品药物管理局（FDA）的真实世界证据计画进一步加速了该地区对真实世界数据的应用。欧洲紧随其后，欧洲癌症资讯系统报告称，每年新增癌症病例约400万例，这为各大肿瘤中心开展真实世界数据（RWE）计画提供了支持。亚太地区预计将实现最快成长，中国国家肿瘤中心预计2023年新增癌症病例将达到480万例，将推动对医疗数据基础设施和数位化肿瘤解决方案的投资。在拉丁美洲和中东等新兴地区，癌症发病率的上升以及政府为加强医疗数据收集所采取的倡议，正在创造新的市场机会。

美国肿瘤真实世界证据市场—国家分析

美国在全球真实世界证据（RWE）肿瘤市场中处于领先地位，这得益于其先进的医疗保健生态系统、广泛的肿瘤研究以及对真实世界数据整合的强有力的监管支持。根据美国国家癌症研究所（NCI）预测，到2024年，美国将新增约190万例癌症病例，因此迫切需要透过真实世界证据来加强治疗评估。美国食品药物管理局（FDA）的真实世界证据计画正在促进更快的核准流程和更完善的上市后监测，从而推动市场成长。 Flatiron Health、IQVIA和Tempus Labs等主要企业正致力于利用庞大的临床数据、人工智慧分析以及与顶尖癌症中心的合作。美国拥有强大的医疗保健IT基础设施，预计2023年医疗保健支出将超过4.3兆美元（CMS数据），并且精准癌症治疗领域不断创新，因此，美国已成为全球肿瘤真实世界证据应用的中心。

目录

第一章 肿瘤真实世界证据市场概述

  • 分析范围
  • 市场估算期

第二章执行摘要

  • 市场区隔
  • 竞争考察

第三章 真实世界证据肿瘤学的关键市场趋势

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 未来市场趋势

第四章 真实世界证据肿瘤市场：产业分析

  • PEST分析
  • 波特五力分析
  • 市场成长展望：概览
  • 管理体制分析

第五章 真实世界肿瘤市场：地缘政治紧张局势加剧的影响

  • 新冠疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章 真实世界证据肿瘤市场概况

  • RWE肿瘤市占率分析（2024年）
  • 主要製造商的细分数据
    • 对现有公司的分析
    • 新兴企业分析

7. 肿瘤学真实世界证据市场（按组成部分划分）

  • 概述
    • 细分市场占有率分析：按组成部分
    • 数据集
      • EMR/HER
      • 宣称
      • 药局
      • 癌症登记处
    • 集成资料集
    • 咨询服务

8. 依资料来源类型分類的 RWE 肿瘤市场

  • 概述
    • 细分市场占有率分析：依资料来源类型划分
    • 临床数据
    • 计费数据
    • 肿瘤登记处
    • 药房数据

9. 按治疗领域分類的RWE肿瘤市场

  • 概述
    • 细分市场占有率分析：依治疗领域划分
    • 乳癌
    • 肺癌
    • 摄护腺癌
    • 骨髓恶性肿瘤
    • 其他的

第十章 按应用分類的RWE肿瘤市场

  • 概述
    • 细分市场占有率分析：按应用
    • 药物研发与核准
    • 市场进入和报销
    • 上市后监测
    • 医疗设备认证
    • 其他的

第十一章：按最终用户分類的RWE肿瘤市场

  • 概述
    • 细分市场占有率分析：依最终用户划分
    • 製药、生技和医疗设备公司
    • 医疗保健提供者
    • 医疗保险公司
    • 其他的

第十二章：按地区分類的RWE肿瘤市场

  • 介绍
  • 北美洲
    • 概述
    • 北美主要製造商
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲主要製造商
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 其他的
  • 亚太地区
    • 概述
    • 亚太地区主要製造商
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 其他的
  • 拉丁美洲
    • 概述
    • 拉丁美洲主要製造商
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 其他的
  • 中东和非洲
    • 概述
    • 中东和非洲的主要製造商
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • 其他的

第十三章 主要供应商分析：真实世界证据肿瘤产业

  • 竞争对手仪錶板
    • 竞争基准
    • 竞争定位
  • 公司简介
    • IQVIA
    • ICON plc
    • Syneos Health
    • Parexel International
    • Covance（Labcorp）
    • PPD, Inc.
    • PRA Health Sciences（now part of ICON）
    • Charles River Laboratories
    • Medidata Solutions（Dassault Systemes）
    • Clarivate
    • Flatiron Health（owned by Roche）
    • Cerner Corporation（now part of Oracle）
    • Cota Healthcare
    • Evidera（PAREXEL）
    • RealEndeavors
    • Truven Health Analytics（IBM Watson Health）
    • Informa Pharma Intelligence
    • McKesson Corporation
    • Symphony Health（ICON）
    • Others

第十四章 AnalystView 360度分析

简介目录
Product Code: ANV5973

RWE oncology market size was valued at US$ 790.10 Million in 2024, expanding at a CAGR of 14.90% from 2025 to 2032.

Real-World Evidence (RWE) in oncology involves the collection and analysis of health data from real-world settings such as electronic health records, patient registries, and insurance claims-to complement clinical trial findings. This evidence supports treatment effectiveness, safety monitoring, and personalized cancer care decisions. The market growth is driven by increasing cancer prevalence and the rising adoption of value-based healthcare models. According to the National Cancer Institute (NCI), an estimated 1.9 million new cancer cases were diagnosed in the U.S. in 2024, intensifying the need for real-world data to improve therapeutic outcomes. Advances in data analytics, AI integration, and regulatory acceptance are fostering RWE applications to accelerate oncology drug development and optimize patient management globally.

RWE Oncology Market- Market Dynamics

Growing adoption of real-world data to enhance oncology treatment outcomes

The rising global cancer burden and the need for personalized, evidence-based oncology care are driving demand for RWE solutions. According to the World Health Organization (WHO), cancer remains a leading cause of death globally, accounting for nearly 10 million deaths in 2024. This has intensified the focus on utilizing real-world data from electronic health records, cancer registries, and claims databases to complement clinical trials, improving treatment effectiveness and safety monitoring. Regulatory agencies like the U.S. FDA increasingly accept RWE to support drug approvals and label expansions, accelerating market adoption. Advances in AI and machine learning facilitate deeper insights from complex oncology data, enabling precision medicine. Furthermore, healthcare payers and providers emphasize value-based care models, leveraging RWE to optimize treatment protocols and reduce costs. Growing investments in health IT infrastructure, particularly in developed and emerging economies, further propel market growth opportunities worldwide.

RWE Oncology Market- Segmentation Analysis:

The Global RWE Oncology Market is segmented on the basis of Component, Data Source Type, Therapeutic Area, Application, End User, and Region.

Based on Component, the market includes Data Sources, Analytics Software, and Services. Data Sources encompass electronic health records (EHRs), cancer registries, claims and billing data, patient-reported outcomes, and genomic databases, providing diverse real-world insights critical for oncology research. Analytics Software leverages AI and machine learning algorithms to analyze complex oncology datasets for treatment effectiveness, safety, and outcome prediction. Services include consulting, data management, and integration, which help healthcare stakeholders implement RWE solutions efficiently. According to the U.S. Office of the National Coordinator for Health Information Technology (ONC), adoption of certified EHR technology reached over 85% among hospitals in 2024, supporting data availability for RWE.

Based on Application, the market covers Drug Development & Clinical Trials, Treatment Optimization, Regulatory & Payer Decision Support, and Market Access & Reimbursement. Drug Development utilizes RWE to complement clinical trials, enabling accelerated approvals and label expansions. Treatment Optimization involves personalizing therapy based on patient data to improve outcomes. Regulatory & Payer Decision Support uses real-world insights for safety monitoring and coverage decisions. Market Access and Reimbursement benefit from RWE by demonstrating treatment value and cost-effectiveness, critical for payer negotiations and formulary inclusion.

RWE Oncology Market- Geographical Insights

The global RWE oncology market shows significant regional variation shaped by healthcare infrastructure, data availability, and regulatory frameworks. North America leads with over 1.9 million new cancer cases projected in the U.S. in 2024, according to the National Cancer Institute (NCI), fueling demand for real-world data to improve treatment outcomes. The FDA's Real-World Evidence Program further accelerates adoption in this region. Europe follows, with the European Cancer Information System reporting nearly 4 million new cancer cases annually, supporting RWE initiatives across major oncology hubs. Asia-Pacific is expected to experience the fastest growth, with China's National Cancer Center estimating 4.8 million new cancer diagnoses in 2023, driving investments in healthcare data infrastructure and digital oncology solutions. Emerging regions such as Latin America and the Middle East benefit from increasing cancer incidence and government efforts to enhance healthcare data collection, presenting new market opportunities.

U.S. RWE Oncology Market- Country Insights

The United States leads the global RWE oncology market, propelled by its advanced healthcare ecosystem, extensive oncology research, and strong regulatory support for real-world data integration. According to the National Cancer Institute (NCI), approximately 1.9 million new cancer cases are expected in the U.S. in 2024, driving urgent demand for enhanced treatment evaluation through real-world evidence. The FDA's Real-World Evidence Program facilitates faster approvals and improved post-market surveillance, strengthening the market's growth. Key players such as Flatiron Health, IQVIA, and Tempus Labs focus on leveraging vast clinical data, AI analytics, and partnerships with leading cancer centers. The U.S.'s robust health IT infrastructure, high healthcare spending exceeding $4.3 trillion in 2023 (CMS), and ongoing innovation in precision oncology make it the focal point for real-world evidence applications in oncology worldwide.

RWE Oncology Market- Competitive Landscape:

The rising emphasis on data-driven oncology treatment and real-world evidence utilization is intensifying competition among key market players. Major companies such as IQVIA, ICON plc, Syneos Health, Parexel, Covance, and Flatiron Health lead by leveraging advanced data analytics platforms, AI integration, and comprehensive oncology data registries. Common strategies include strategic acquisitions to enhance data capabilities, partnerships with pharmaceutical companies for tailored oncology solutions, and expanding global footprints to access diverse patient populations. Investment in cloud-based data management and real-time evidence generation tools is prevalent, enabling faster drug development and regulatory approvals. Additionally, companies are focusing on compliance with evolving data privacy regulations and offering customized solutions to meet oncology research demands, strengthening their competitive positions worldwide.

Recent Developments:

In May 2025, Datavant completed its acquisition of RWE specialist Aetion, combining data connectivity and advanced real world evidence analytics into a unified platform. The expanded ecosystem-spanning over 300 data partners across EHRs, claims, registries, and more-aims to help life sciences and healthcare organizations generate faster, scalable, and actionable evidence across the drug development lifecycle.

In April 2025, Atropos Health partnered with Ontada to integrate Ontada's community oncology real world data into the Atropos Evidence(TM) Network, enhancing RWE use cases for clinicians, researchers, and healthcare leaders. This collaboration aims to improve cancer care protocols, advance precision medicine, and accelerate development of new oncology treatments using high quality real world evidence.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL RWE ONCOLOGY MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • IQVIA
  • ICON plc
  • Syneos Health
  • Parexel International
  • Covance (Labcorp)
  • PPD, Inc.
  • PRA Health Sciences (now part of ICON)
  • Charles River Laboratories
  • Medidata Solutions (Dassault Systemes)
  • Clarivate
  • Flatiron Health (owned by Roche)
  • Cerner Corporation (now part of Oracle)
  • Cota Healthcare
  • Evidera (PAREXEL)
  • RealEndeavors
  • Truven Health Analytics (IBM Watson Health)
  • Informa Pharma Intelligence
  • McKesson Corporation
  • Symphony Health (ICON)
  • Others

GLOBAL RWE ONCOLOGY MARKET, BY COMPONENT- MARKET ANALYSIS, 2019 - 2032

  • Datasets
  • EMR/HER
  • Claims
  • Pharmacy
  • Cancer Registries
  • Integrated Datasets
  • Consulting Services

GLOBAL RWE ONCOLOGY MARKET, BY DATA SOURCE TYPE- MARKET ANALYSIS, 2019 - 2032

  • Clinical Data
  • Claims Data
  • Oncology Registries
  • Pharmacy Data

GLOBAL RWE ONCOLOGY MARKET, BY THERAPEUTIC AREA- MARKET ANALYSIS, 2019 - 2032

  • Breast Cancer
  • Lung Cancer
  • Prostate Cancer
  • Hematologic Malignancies
  • Others

GLOBAL RWE ONCOLOGY MARKET, BY APPLICATION- MARKET ANALYSIS, 2019 - 2032

  • Drug Development & Approvals
  • Market Access & Reimbursement
  • Post-Market Surveillance
  • Medical Device Approvals
  • Others

GLOBAL RWE ONCOLOGY MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Pharmaceutical, Biotechnology & Medical Device Companies
  • Healthcare Providers
  • Healthcare Payers
  • Others

GLOBAL RWE ONCOLOGY MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. RWE Oncology Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. RWE Oncology Market Snippet by Component
    • 2.1.2. RWE Oncology Market Snippet by Data Source Type
    • 2.1.3. RWE Oncology Market Snippet by Therapeutic Area
    • 2.1.4. RWE Oncology Market Snippet by Application
    • 2.1.5. RWE Oncology Market Snippet by End User
    • 2.1.6. RWE Oncology Market Snippet by Country
    • 2.1.7. RWE Oncology Market Snippet by Region
  • 2.2. Competitive Insights

3. RWE Oncology Key Market Trends

  • 3.1. RWE Oncology Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. RWE Oncology Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. RWE Oncology Market Opportunities
  • 3.4. RWE Oncology Market Future Trends

4. RWE Oncology Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. RWE Oncology Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. RWE Oncology Market Landscape

  • 6.1. RWE Oncology Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. RWE Oncology Market - By Component

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Component, 2024 & 2032 (%)
    • 7.1.2. Datasets
      • 7.1.2.1. EMR/HER
      • 7.1.2.2. Claims
      • 7.1.2.3. Pharmacy
      • 7.1.2.4. Cancer Registries
    • 7.1.3. Integrated Datasets
    • 7.1.4. Consulting Services

8. RWE Oncology Market - By Data Source Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Data Source Type, 2024 & 2032 (%)
    • 8.1.2. Clinical Data
    • 8.1.3. Claims Data
    • 8.1.4. Oncology Registries
    • 8.1.5. Pharmacy Data

9. RWE Oncology Market - By Therapeutic Area

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Therapeutic Area, 2024 & 2032 (%)
    • 9.1.2. Breast Cancer
    • 9.1.3. Lung Cancer
    • 9.1.4. Prostate Cancer
    • 9.1.5. Hematologic Malignancies
    • 9.1.6. Others

10. RWE Oncology Market - By Application

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Application, 2024 & 2032 (%)
    • 10.1.2. Drug Development & Approvals
    • 10.1.3. Market Access & Reimbursement
    • 10.1.4. Post-Market Surveillance
    • 10.1.5. Medical Device Approvals
    • 10.1.6. Others

11. RWE Oncology Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Pharmaceutical, Biotechnology & Medical Device Companies
    • 11.1.3. Healthcare Providers
    • 11.1.4. Healthcare Payers
    • 11.1.5. Others

12. RWE Oncology Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. RWE Oncology Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. RWE Oncology Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. RWE Oncology Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. RWE Oncology Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. RWE Oncology Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Component, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Data Source Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Therapeutic Area, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Application, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- RWE Oncology Industry

  • 13.1. Competitive Benchmarking
    • 13.1.1. Competitive Dashboard
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. IQVIA
    • 13.2.2. ICON plc
    • 13.2.3. Syneos Health
    • 13.2.4. Parexel International
    • 13.2.5. Covance (Labcorp)
    • 13.2.6. PPD, Inc.
    • 13.2.7. PRA Health Sciences (now part of ICON)
    • 13.2.8. Charles River Laboratories
    • 13.2.9. Medidata Solutions (Dassault Systemes)
    • 13.2.10. Clarivate
    • 13.2.11. Flatiron Health (owned by Roche)
    • 13.2.12. Cerner Corporation (now part of Oracle)
    • 13.2.13. Cota Healthcare
    • 13.2.14. Evidera (PAREXEL)
    • 13.2.15. RealEndeavors
    • 13.2.16. Truven Health Analytics (IBM Watson Health)
    • 13.2.17. Informa Pharma Intelligence
    • 13.2.18. McKesson Corporation
    • 13.2.19. Symphony Health (ICON)
    • 13.2.20. Others

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us